What's Happening?
Turn Therapeutics has reported promising stability data for its intranasal vaccine candidate, which could reduce the need for ultra-cold storage. The vaccine, using the rVSV-MARV vector in Turn's PermaFusion delivery system, showed viability for 14 days at room temperature and 28 days under refrigeration. This development marks a significant advancement in vaccine storage and distribution, potentially allowing vaccines to reach remote and underserved areas without the need for -80°C storage. Turn Therapeutics plans further stability studies and exploratory immunogenicity studies to assess immune responses.
AD
Why It's Important?
The ability to store vaccines at higher temperatures could revolutionize vaccine distribution, especially in areas lacking infrastructure for ultra-cold storage. This could improve access to vaccines in remote and conflict-affected regions, enhancing global health security and emergency preparedness. The innovation could also reduce costs associated with vaccine storage and transportation, benefiting healthcare systems worldwide. Turn Therapeutics' approach may set a precedent for future vaccine development, emphasizing stability and accessibility.
What's Next?
Turn Therapeutics plans to conduct further stability studies to evaluate longer storage durations, including 60, 90, and 180 days. The company also intends to initiate in vivo immunogenicity studies to assess the vaccine's immune response. If successful, these studies could lead to broader applications of the technology in routine immunization campaigns and outbreak responses. The company is focused on improving vaccine access and outcomes, potentially influencing future vaccine development strategies.
